Efficacy and Safety of a New Botulinum Toxin Type A Free of Complexing Proteins
MT10107 is botulinum neurotoxin type A derived drug which utilizes the 150 kDa portion without complexing proteins and human serum albumin contents. To evaluate the efficacy and the safety of MT10107, it was compared with onabotulinumtoxinA in this double-blind, randomized controlled trial. Twenty-f...
Main Authors: | Hyun-Mi Oh, Joo Hyun Park, Dae Heon Song, Myung Eun Chung |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-12-01
|
Series: | Toxins |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6651/8/1/4 |
Similar Items
-
Centrally mediated late motor recovery after botulinum toxin injection: Case reports and a review of current evidence
by: Manuel F. Mas, et al.
Published: (2017-07-01) -
Efficacy of Botulinum Toxin B Injection for Raynaud’s Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis
by: Sei-ichiro Motegi, et al.
Published: (2017-04-01) -
Value of botulinum toxin injections preceding a comprehensive rehabilitation period for children with spastic cerebral palsy: A cost-effectiveness study
by: Fabienne Schasfoort, et al.
Published: (2017-09-01) -
Intraoral alveolar submucosal injections of Incobotulinumtoxin A: Relief of therapy-refractory trigeminal neuropathy after tooth extraction
by: Lars Wojtecki, et al.
Published: (2021-12-01) -
The Safety and Effect of Local Botulinumtoxin A Injections for Long-Term Management of Chronic Pain in Post-Herpetic Neuralgia: Literature Review and Cases Report Treated with Incobotulinumtoxin A
by: Songjin Ri, et al.
Published: (2021-07-01)